MDS risk based on IPSS score

PATIENT PRESENTATION

- Low Risk or Intermediate I
- High Risk or Intermediate II

MDS risk based on IPSS score

TREATMENT

- Consider clinical trials
- Iron chelation
- Growth factors
- Hypomethylating agents
- Lenalidomide (if 5q deletion present)

Response?

- Yes
  - Surveillance as per protocol
- No
  - Clinical trials
  - Surveillance

SURVEILLANCE

- Yes
  - Surveillance as per protocol
- No
  - Allogeneic stem cell transplant
  - Clinical trials
  - Surveillance

1 Greater than or equal to 18 years old

2 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

3 MDS risk is calculated utilizing the International Prognostic Scoring System (IPSS) score, which includes percent of blast, cytogenetics, and number of cytopenias


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Note: Consider clinical trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a comprehensive cancer center.
Myelodysplastic Syndrome (MDS) - Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

Myelodysplastic Syndrome (MDS) - Adult

This practice algorithm is based on majority expert opinion of the Leukemia Center Faculty workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

- Yesid Alvarado, MD (Leukemia)
- Michael Andreeff, PhD, MD (Leukemia)
- Christopher Benton, MD (Leukemia)
- Kapil Bhalja, MD (Leukemia)
- Gautam Borthakur, MBBS (Leukemia)
- Prithviraj Bose, MD (Leukemia)
- Jan Burger, MD (Leukemia)
- Jorge Cortes, MD (Leukemia)
- Naval Daver, MD (Leukemia)
- Courtney DiNardo, MD (Leukemia)
- Zeev Estrov, MD (Leukemia)
- Alessandra Ferrajoli, MD (Leukemia)
- Emil Freireich, MD (Leukemia)
- Wendy Garcia, BS*
- Guillermo Garcia-Manero, MD (Leukemia)
- Ghayas Issa, MD (Leukemia)
- Elias Jabbour, MD (Leukemia)
- Nitin Jain, MBBS (Leukemia)
- Tapan Kadia, MD (Leukemia)

- Hagop M. Kantarjian, MD (Leukemia)†
- Michael Keating, MD (Leukemia)
- Marina Konopleva, MD (Leukemia)
- Steven Kornblau, MD (Leukemia)
- Lucia Masarova, MD (Leukemia)
- Guillermo Montalban-Bravo, MD (Leukemia)
- Kiran Naoji, MD (Leukemia)
- Maro Ohanian, DO (Leukemia)
- Naveen Pemmaraju, MD (Leukemia)
- Farhad Ravandi-Kashani, MD (Leukemia)
- Mary Beth Rios, RN (Leukemia)
- Michael Ryffling, MD (Pediatrics)
- Koji Sasaki, MD (Leukemia)
- Nicholas Short, MD (Leukemia)
- Koichi Takahashi, MD (Leukemia)
- Philip Thompson, MBBS (Leukemia)
- Srdan Verstovsek, MD (Leukemia)
- William Wierda, MD (Leukemia)
- Sonal Yang, PharmD*
- Musa Yilmaz, MD (Leukemia)

† Core Development Leads
* Clinical Effectiveness Development Team